title: [The advantage of preventive vaginal antisepsis with hexetidine in obstetrics and gynecology].
abstract: In five studies, the advantage of repeated vaginal prophylaxis by a new preparation of hexetidine vaginal suppositories (10 mg) was investigated prospectively, randomised and method-controlled (n = 2 x 50). After a five-day application, the hexetidine group achieved bacterial reductions of five log CFU/ml in the vagina and nearly three log CFU/ml in the cervix uteri, whilst no reduction was found in the controls at any time (p less than 0.01). The reduction of individual bacterial species was investigated in 224 pregnant and also gynaecological patients. In cases of impending preterm childbirth, a five-day application of 20 mg hexetidine/day could reduce all bacteria sufficiently with the exception of lactobacilli; especially beta Streptococci were reduced. The same was achieved by a three-day application of 10 mg hexetidine/day pre-operatively. A long-term study in 11,724 deliveries showed, that neonatal infectious mortality and morbidity after 36 gestational weeks could be reduced significantly by hexetidine. The new hexetidine preparation appeared to be efficient in vaginal antisepsis, especially in pregnancy. A favourable lactobacilli-selective effect was demonstrated. Since the importance of lactobacilli in vaginal ecology is known, hexetidine prophylaxis must be considered as advantageous in Obstetrics and Gynecology. From a practical and economic point of view, the application of hexetidine as vaginal suppositories appears favourable compared to antiseptic solutions.
authors.affiliation: Frauenklinik, Klinikum Bayreuth.
authors.forename: H
authors.initials: H
authors.lastname: Weidinger
authors.forename: H J
authors.initials: HJ
authors.lastname: Passloer
authors.forename: L
authors.initials: L
authors.lastname: Kovacs
authors.forename: B
authors.initials: B
authors.lastname: Berle
mesh_terms: D000328:Adult; D002584:Cervix Uteri / Q000382:microbiology; D002821:Chorioamnionitis / Q000382:microbiology / Q000517:prevention & control*; D015169:Colony Count, Microbial; D005260:Female; D005831:Genital Diseases, Female / Q000382:microbiology / Q000601:surgery*; D006590:Hexetidine / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007231:Infant, Newborn; D007752:Obstetric Labor, Premature / Q000382:microbiology; D011247:Pregnancy; D011300:Preoperative Care / Q000379:methods*; D011446:Prospective Studies; D011645:Puerperal Infection / Q000382:microbiology / Q000517:prevention & control*; D013530:Surgical Wound Infection / Q000382:microbiology / Q000517:prevention & control*; D014621:Vagina / Q000187:drug effects / Q000382:microbiology*
chemical_list: D006590:Hexetidine
vernacular_title: Nutzen der prophylaktischen Vaginalantiseptik mit Hexetidin in Geburtshilfe und Gynäkologie.